In the waiting rooms of Department of Veterans Affairs clinics across the country, a quiet conversation has been taking place for years — veterans describing cannabis use to providers who are legally prohibited from helping them use it safely. VA physicians cannot recommend state-legal cannabis, cannot document it in ways that trigger referrals, and until recently, could not even discuss it without risking their medical licenses.
A bipartisan coalition in the House and Senate is pushing Cannabis Inquirer’s legislative tracker to end that prohibition, and for the first time, advocates say the policy environment may be catching up to the clinical reality.
The Policy Gap
Federal law currently bars VA physicians from recommending medical cannabis even in states where it is fully legal. This prohibition stems from cannabis’s Schedule I classification under the Controlled Substances Act, which designates the drug as having no accepted medical use — a classification that the HHS’s own scientific review contested in its rescheduling recommendation.
The practical effect: veterans who use state-legal cannabis for pain, PTSD, or sleep disorders are effectively managing those conditions outside the VA health system, without provider guidance, without documentation, and without the kind of oversight that reduces adverse events and drug interactions.
According to surveys conducted by the Veterans Cannabis Project, more than one in three veterans in states with legal cannabis programs use it for a medical purpose. Of those, fewer than one in five have discussed it with their VA provider — not because they don’t want to, but because they’ve been told it can’t be discussed.
The Research Base
The prohibition has persisted despite a growing research literature on cannabis and veteran health outcomes. A 2024 peer-reviewed study in the Journal of Psychoactive Drugs found that veterans with PTSD who incorporated cannabis into their treatment plans reported significant reductions in nightmare frequency, hypervigilance, and sleep disruption — three of the core symptom clusters that most impair quality of life.
The study, which followed 150 veterans over 18 months, found no statistically significant increase in cannabis use disorder diagnoses compared to a matched control group, addressing a concern frequently raised by opponents of veteran cannabis access.
Earlier research has shown similarly promising signals for chronic pain — one of the most common conditions in the veteran population — with multiple studies suggesting cannabis can reduce opioid use in pain patients, a particularly significant finding given the veteran opioid mortality rate.
None of this research is definitive. Cannabis research has historically been hampered by the Schedule I classification, which restricts federally funded studies and creates regulatory barriers to clinical trial enrollment. The evidence base, while growing, would not meet FDA approval standards for a pharmaceutical indication.
That limitation has been used by VA leadership to justify the current policy — but critics argue it is circular: restricting research while citing the absence of research as justification for restriction.
The Legislation
The Veterans Equal Access Act, which has been introduced in multiple sessions without reaching a floor vote, would allow VA physicians to complete paperwork required under state medical cannabis programs for eligible veterans. It would not require VA to provide cannabis, fund it, or endorse it — simply allow providers to participate in state regulatory frameworks.
A companion bill, the Veterans Cannabis Research Act, would direct the VA to conduct clinical trials on cannabis as a treatment for PTSD and chronic pain, removing some of the administrative barriers that have impeded research.
Both bills have co-sponsors from both parties, including members who have generally opposed cannabis legalization but represent states with large veteran populations and active medical cannabis programs.
Resistance and Counterarguments
The VA has historically opposed these bills, citing concern about the conflict with federal law and the liability implications of recommending a Schedule I substance. The American Legion, the largest veteran service organization in the United States, shifted its official position to support medical cannabis access in 2016, but some smaller VSOs maintain opposition on grounds of potential mental health risks, particularly for younger veterans.
Critics also point to cannabis as a risk factor for psychosis in vulnerable populations — a finding from the psychiatric literature that cannabis advocates argue applies to recreational use patterns, not the lower-dose, regulated medical use being contemplated.
The Human Equation
Behind the policy debate are individual veterans who have navigated the system and found it lacking. A Marine Corps veteran from North Carolina, reached by CannabisInquirer at a Veterans Cannabis Project advocacy event, described using cannabis for chronic pain after two knee surgeries — stopping opioid painkillers within six months.
“My VA doctor knows I use it,” he said. “He just can’t say anything. He gave me a look and said, ‘I can’t advise you on that, but keep monitoring how you feel.’ That’s the best he could do. That’s not medicine. That’s a workaround.”
For veterans like him, the legislation isn’t about cannabis policy. It’s about whether their healthcare can catch up to their lives.
Related Stories
Responses